

Nizoral^{TRADEMARK}

(ketoconazole) (tablets)

over 3 million prescriptions world-wide:

the new beginning in antifungal therapy.



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but problematic fungal infections

can now be treated effectively *and* conveniently. Typically, in recurrent *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.



JANSSEN
PHARMACEUTICA

the drug discovery company

Prescribing Information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole.

Uses: Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I.-tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed.

Side effects, precautions, contra-indications: contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole; these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels. On the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynaecomastia has been reported.



Heceta lighthouse, Oregon, USA

Prescribing Information

Presentation Vials containing 500mg, 1g or 2g of cefotaxime sodium. **Indications** Infections before identification of the organism. Infections caused by bacteria of established sensitivity, including chest infections, septicaemia, urinary tract infections, soft tissue infections, obstetric and gynaecological infections, bone and joint infections, meningitis, gonorrhoea. **Dosage** Claforan is administered i.m. or i.v. **Adults:** Usually 2-6g daily (see full prescribing information). For infections caused by sensitive *Pseudomonas* spp., doses of more than 6g daily are usually required. **Children:** 100-150mg/kg/day in 2 to 4 divided doses. Up to 200mg/kg/day may be given in very severe infections. **Neonates:** 50mg/kg body weight daily in 2 to 4 equally divided doses. In cases of severe infection, divided daily doses of 150-200mg/kg have been given. **Dosage in renal impairment** Reduced dosage is only required in severe renal failure (GFR < 5ml/min = serum creatinine approx. 751 µmol/l) when, after an initial loading dose of 1g, the daily dose is halved without change in frequency of dosing. **Contra-indications** Known allergy to cephalosporins. **Precautions** Cephalosporin antibiotics may usually be given safely to patients who

are hypersensitive to penicillins, although cross reactions have been reported. Special care is indicated in patients who have had an anaphylactic response to penicillin. Patients with severe renal dysfunction — see previous. Cephalosporin antibiotics at high dosage should be given with caution to patients receiving aminoglycoside antibiotics or potent diuretics such as frusemide. At recommended doses, enhancement of nephrotoxicity is unlikely with Claforan. A false-positive reaction to glucose may occur with reducing substances. Claforan should not be mixed in the syringe with aminoglycoside antibiotics. The safety of Claforan in human pregnancy has not been established. **Side effects** Adverse reactions are rare and generally mild and transient, but include diarrhoea (pseudomembranous colitis has been rarely reported), candidiasis, rashes, fever, eosinophilia, leukopenia, transient rises in liver transaminase and alkaline phosphatase, transient pain at the site of injection and phlebitis. **Product licence holder and number** Roussel Laboratories Ltd., Broadwater Park, North Orbital Road, Uxbridge, Middlesex UB9 5HP. 0109/0074. **Package quantities and basic N.H.S. price** Vials of 500mg, 1g and 2g in packs of 10. One gram vial £4.95. **Date of preparation** November 1984.

ROUSSEL



35 Boulevard des Invalides,
75007 Paris, Cedex 07, France

THE ROYAL COLLEGE OF SURGEONS OF EDINBURGH

Nicholson Street, Edinburgh

LISTER PROFESSORSHIP AND LECTURE

The Lister Professorship and Lecture is awarded annually in recognition of an outstanding piece of original research by a medical practitioner under 40 years of age engaged in any branch of surgery.

The Lister Professor will receive an honorarium of £100, together with a travel grant generously supported by Johnson and Johnson Limited to enable him to attend international scientific meetings in other centres.

Candidates for the award are invited to submit a synopsis of their subject (approximately 500 words) to the Honorary Secretary of the College by 31 May 1985. The Lister Lecture will be delivered in 1985/86 and, in accordance with the terms of the award, the substance of the research must not have been published or submitted for publication before the date chosen for the lecture.

LETTERS TO A YOUNG DOCTOR

PHILIP RHODES

Faced with increasing competition and even the prospect of unemployment young doctors need sound advice on how they should plan their careers. This series of articles by Professor Philip Rhodes, begins with advice to preregistration house officers and then considers the choice open to them after registration. There are sections on study leave, applying for jobs, and interviews, and chapters giving special advice to women and overseas doctors. Examinations, research, teaching, administration, and postgraduate education are also covered.

Price: Inland £6.00
Overseas £8.00/USA\$14.00
(Inland £5.50; Overseas £7.50/USA\$13.00
to BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now

From: The Publisher, British Medical Journal,
BMA House, Tavistock Square, London WC1H 9JR
or any leading bookseller

Just published

HOW TO DO IT

SECOND EDITION

The first edition of HOW TO DO IT proved a useful and popular guide to those things a doctor needs to know but is rarely taught: how to take an examination, how to interview and be interviewed, how to plan and write up research, how to behave at an inquest. In the second edition the original chapters have been expanded and updated, and there are several more chapters on new challenges—choosing a computer, flying, holding a press conference—and on some older ones not included in the first edition—assessing a job, dealing with a publisher.

Price: Inland £6.50
Abroad £9.00/USA\$14.50
BMA members: Inland £6.00
Abroad £8.50/USA\$13.50
*including postage, by air
abroad*

Please quote
membership number

**Payment must be enclosed
with order**

Order from
The Publishing Manager
British Medical Journal
BMA House, Tavistock Square
London WC1H 9JR
or any leading bookseller

All over the world doctors know

WHEN IT COMES
TO DIARRHOEA
NOTHING WORKS
LIKE **Imodium** TRADEMARK
loperamide

© JANSSEN PHARMACEUTICA 1984

Oral rehydration and
the case for Imodium

In acute diarrhoea it is often essential to treat dehydration by administering fluids intravenously or by mouth. Oral rehydration therapy will significantly improve the rate of absorption, but it can hardly reduce excessive secretion of fluids and electrolytes.

Imodium has been shown to reduce the excessive secretion into the intestinal lumen. In fact, Imodium can enhance the restoring effect of rehydration fluids and expedite the patient's recovery.



JANSSEN
PHARMACEUTICA

the drug discovery company

References: Hughes, S., Higgs, N.B., Turnberg, L.A.: Loperamide has anti-secretory activity in the human jejunum *in vivo*. In press.
Sandhu, B.K., Tripp, J.H., Milla, P.J., Harries, J.T.: Loperamide in severe protracted diarrhoea. *Arch. Dis. Child.* 58, 39 (1983)



The Cardio-Protectors

TENORMIN FOR MODERATE HYPERTENSION
TENORMIN LS FOR MILD AND OLDER HYPERTENSIVES

'Tenormin' and 'Tenormin' LS Prescribing Notes

PRESENTATION: 'Tenormin' tablets containing atenolol 100mg are round, bi-convex, orange and film coated. 'Tenormin' LS tablets containing atenolol 50mg are round, bi-convex, orange and film coated.

USES: Management of Hypertension.

DOSAGE: 'Tenormin' 100mg orally once a day and 'Tenormin' LS orally once a day; some patients may respond adequately to 'Tenormin' low strength.

CONTRAINDICATIONS: Heart Block.

PRECAUTIONS: Untreated cardiac failure, bradycardia, renal failure, anaesthesia, pregnancy. Caution in patients with chronic obstructive airways disease. 'Tenormin' modifies the tachycardia of hypoglycaemia. Co-administration of verapamil or Class I antidysrhythmic agents. Withdrawal of clonidine. Withdrawal of beta-blocking drugs should be gradual in patients with ischaemic heart disease.

SIDE EFFECTS: Coldness of extremities, bradycardia and muscular fatigue may occur. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta-blockers—consider discontinuance if they occur.

PACK SIZE AND BASIC NHS COST: 'Tenormin' 28's £6.98; 'Tenormin' LS 28's £4.88.

PRODUCT LICENCE NUMBER: 'Tenormin' 29/122; 'Tenormin' LS 29/86.

'Tenormin', 'Tenormin' LS are trademarks.



Full prescribing information is available on request to the Company.
Stuart Pharmaceuticals Limited,
 Carr House, Carrs Road, Cheadle, Cheshire, SK8 2EG.

